TSX runs higher on rate cut expectations
NEW YORK - Flatiron Health, a subsidiary of pharmaceutical giant Roche (market cap: $276.55B), announced Wednesday the appointment of Nathan Hubbard as Chief Executive Officer, succeeding Carolyn Starrett who will transition to a senior advisor role after leading the company since 2021. According to InvestingPro, Roche maintains strong financial health with $80.02B in revenue over the last twelve months.
Hubbard brings over 20 years of leadership experience across biopharma, healthcare and data-driven businesses to the oncology-focused healthtech company. He previously served in multiple senior leadership roles at Flatiron, including building the company’s international business. Parent company Roche has demonstrated consistent performance, with InvestingPro data showing a healthy 74.79% gross profit margin and stable dividend payments for 34 consecutive years.
"I’m honored to step into this role," Hubbard said in a press release statement. "I’m committed to building on the strong foundation Carolyn and the team have created."
During Starrett’s tenure as CEO, Flatiron expanded its real-world data platform from 400,000 to more than 5.5 million patients and launched its evidence services business. She also oversaw the company’s global expansion to the United Kingdom, Germany and Japan. Under her leadership, Flatiron’s electronic health record grew to serve over 4,500 providers across the US.
"It’s been the honor of my career to lead Flatiron over the last four and a half years," Starrett said. "We’ve never been in a stronger position."
Thomas Schinecker, CEO of Roche, which owns Flatiron Health as an independent affiliate, expressed confidence in the leadership transition.
"Nathan’s combination of entrepreneurial drive, operational depth, and strong alignment with Flatiron’s mission makes him the right leader to carry the business forward," Schinecker said.
Flatiron Health specializes in oncology point of care solutions and uses real-world data to advance cancer research and treatment. For detailed analysis of Roche’s performance and 8 additional exclusive ProTips, visit InvestingPro, where you’ll find comprehensive research reports covering 1,400+ top stocks with expert insights and actionable intelligence.
In other recent news, Genentech faced a setback as the U.S. Food and Drug Administration rejected its application for Columvi, intended for the second-line treatment of diffuse large B-cell lymphoma. The FDA’s decision was based on insufficient evidence from the STARGLO study to support its proposed indication. Meanwhile, Genentech announced positive results from its Phase III SUNMO study, where Lunsumio combined with Polivy showed significant improvement in outcomes for patients with relapsed or refractory large B-cell lymphoma. These developments highlight Genentech’s ongoing efforts in cancer treatment research. Additionally, Roche, Genentech’s parent company, revealed plans to invest up to $550 million by 2030 to expand its Diagnostics site in Indianapolis. This expansion aims to enhance the manufacturing of continuous glucose monitoring systems. The investment underscores Roche’s commitment to innovation and improving patient care. These recent developments provide a glimpse into the strategic directions of both Genentech and Roche.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.